Actively Recruiting
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Led by Shandong University · Updated on 2023-10-10
50
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
Sponsors
S
Shandong University
Lead Sponsor
S
Shandong Provincial Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.
CONDITIONS
Official Title
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years old
- Pregnant women whose babies are at high risk of developing early-onset sepsis after birth and require preventive or therapeutic antibiotics including piperacillin/tazobactam
- Patients and their families fully understand the study and have signed the informed consent form
You will not qualify if you...
- Intolerance or serious adverse reactions to antibiotic use
- Patients who stopped using piperacillin/tazobactam more than 24 hours before delivery
- Receiving other systemic trial drugs
- Other factors deemed unsuitable for inclusion by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shandong Provincial Hospital
Jinan, China
Actively Recruiting
Research Team
W
Wei Zhao, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here